[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"new-onset-generalized-myasthenia-gravis-gmg\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:new-onset-generalized-myasthenia-gravis-gmg":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100585964","phase-4-a-study-to-evaluate-the-clinical-outcomes-of-efgartigimod-ph20-sc-in-adults-with-new-onset-generalized-myasthenia-gravis-gmg-100585964",false,"NCT06909214","A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)","A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis","ADAPT-EARLY","Inclusion Criteria:\n\n* Is at least 18 years when signing the ICF\n* Has been diagnosed with gMG of MGFA class II, III, or IV\n* Is seropositive for AChR-Ab\n* Is treatment-naive for gMG or has been administered AChEI for the treatment of gMG\n* Had onset of generalized MG signs and\u002For symptoms within 12 months before screening; candidates who also had onset of ocular MG signs and\u002For symptoms within 24 months before screening may be enrolled in the study\n* Has an MG-ADL score ≥5\n\nExclusion Criteria:\n\n* gMG diagnosis of MGFA class I or V\n* Underwent a thymectomy prior to screening, except thymectomy for treatment of nonmalignant thymoma prior to the gMG diagnosis\n* Prior or current use of any of any systemic corticosteroid therapy or nonsteroidal immunosuppressive therapy for the treatment of gMG","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The main purpose of this study is to measure how well adults with new-onset gMG (which means they've had generalized disease signs and\u002For symptoms for less than 1 year) respond to treatment with efgartigimod PH20 SC. The study consists of a treatment period of 51 weeks. The study duration for each participant will be approximately 58 weeks.",[27],"New Onset Generalized Myasthenia Gravis (gMG)","RECRUITING","2026-03-09",{"date":31,"type":32},"2026-03-10","ACTUAL",{"date":34,"type":32},"2025-04-17",{"date":36,"type":21},"2027-05",{"name":38,"class":39},"argenx","INDUSTRY",18]